The diagnosis and treatment of cancer-related neuropathic pain (CRNP) varies widely, according to results of a survey conducted in 13 European countries. The survey results were presented by researchers at EAN 2022.
Thanks to treatment advances, patients with cancer are living longer, the researchers noted. However, they often live with sequelae, including CRNP.